[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].

Abstract

Treatment of visceral and cutaneous leishmaniasis rests on pentavalent antimonial drugs. However, side effects are often a problem and resistance may emerge. N-methyl-glucamine given for kala-azar induced hematologic or hepatic toxicity in three patients and failed in two. Four patients with cutaneous leishmaniasis recovered but two exhibited adverse side effects. Sodium stibo-gluconate failed in one of three kala-azar patients and in one of two patients with cutaneous leishmaniasis. The effects of these two drugs are discussed, as well as indications of pentamidine and splenectomy.

• Authors: P Bourée, M L Anciaux, P Taugourdeau
• Journal: Pathologie-biologie (Pathol Biol (Paris)) Vol. 33 Issue 5 Pt 2 Pg. 607-10 (Jun 1985) ISSN: 0369-8114 [Print] France
• Vernacular Title: Antimoniate de méthyl-glucamine et stibo-gluconate de sodium dans le traitement des leishmanioses. Etude de seize cas.
• PMID: 3003657 (Publication Type: Journal Article)

Chemical References

• Gluconates
• Organometallic Compounds
• Pentamidine
• Meglumine
• Meglumine Antimoniate
• Antimony
• Antimony Sodium Gluconate

Topics

• Adolescent
• Adult
• Antimony (adverse effects, therapeutic use)
• Antimony Sodium Gluconate (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Female
• Gluconates (therapeutic use)
• Humans
• Infant
• Leishmaniasis (drug therapy, therapy)
• Leishmaniasis, Visceral (drug therapy, therapy)
• Male
• Meglumine
• Meglumine Antimoniate
• Organometallic Compounds
• Pentamidine (therapeutic use)
• Splenectomy